The Economist2d
The bad side-effects of China’s campaign to cut drug costs
These are some of the problems that doctors have encountered in China’s public hospitals. They have been speaking out in recent weeks, questioning the quality of the country’s drugs and urging reform ...
In China, Rare Dissent Over a Program to Save on Drug Costs
Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.
Vyluma Announces Acceptance of Drug Application for NVK002 by China’s National Medical Products Administration (NMPA)
With its acceptance by the NMPA, NVK002 is now under regulatory review across three major global markets: the United States, the European Union, and China. This milestone reinforces Vyluma’s vision of ...
BioWorld16d
China deepens drug, device reforms, aims to be global powerhouse
China is deepening its regulatory reforms of drugs and devices to foster a globally competitive innovation ecosystem to transform China from a major pharmaceutical manufacturer into a global ...
Hosted on MSN4d
IceCure submits application to China’s NMPA for cryoablation system approval
IceCure Medical has submitted a regulatory filing to China's National Medical Products Administration (NMPA) seeking the ...
GSK announces new drug applications accepted for review in China, Japan
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...
Business Insider3y
China's biotech industry has quietly surged to a $180 billion behemoth. Here's how it's reshaping biotech as we know it, from M&A to drug pricing
Many biotechs that spend most of their money on the costly process ... in China to the US market. In 2019, BeiGene won a milestone FDA approval for the first Chinese-developed cancer drug to ...